Molecular classification of gastric cancer: A new paradigm

Clinical Cancer Research

Volumn 17, Issue 9, 2011, Pages 2693-2701

  Shah, Manish A ^a   Khanin, Raya ^a   Tang, Laura ^a   Janjigian, Yelena Y ^a   Klimstra, David S ^a   Gerdes, Hans ^a   Kelsen, David P ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; PROSTATE STEM CELL ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER LOCALIZATION; CANCER SCREENING; CANCER STAGING; CONTROLLED STUDY; DOWN REGULATION; ENDOSCOPIC BIOPSY; FEMALE; GASTROSCOPY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LAPAROSCOPY; MAJOR CLINICAL STUDY; MALE; OCCULT CANCER; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RNA PROCESSING; STOMACH ADENOCARCINOMA; STOMACH CANCER; UPREGULATION;

ADENOCARCINOMA; ADULT; AGED; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM STAGING; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 79955500519     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2203     Document Type: Article

References (41)

1. Parkin DM, Bray FI, Ferlay J, Pisani P. Global cancer statistics: 2002. CA Cancer J Clin 2005;55:74-108.
2. Lauren T. The two histologic main types of gastric carcinoma. Acta Pathol Microbiol Scand 1965;64:34.
3. You WC, Blot WJ, Li JY, Chang YS, Jin ML, Kneller R, et al. Precancerous gastric lesions in a population at high risk of stomach cancer. Cancer Res 1993;53:1317-21. (Pubitemid 23097109)
4. Correa P, Haenszel W, Cuello C, Zavala D, Fontham E, Zarama G, et al. Gastric precancerous process in a high risk population: cross-sectional studies. Cancer Res 1990;50:4731-6. (Pubitemid 20230421)
5. Peek RMJ, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2002;2:28-37. (Pubitemid 37328805)
6. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-9.
7. Carneiro F, Huntsman DG, Smyrk TC, Owen DA, Seruca R, Pharoah P, et al. Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and it's implications for patient screening. J Pathol 2004;203:681-7. (Pubitemid 38714105)
8. Blot WJ, DeVesa SS, Kneller RW, Fraumeni JF. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. J Am Med Assoc 1991:1287-9.
9. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol 2006;12:354-62. (Pubitemid 43329250)
10. Power DG, Kelsen DP, Shah MA. Advanced gastric cancer-slow but steady progress. Cancer Treat Rev 2010.
11. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406.
12. Sørlie T, Perou CM, Tibshirani R, Aas T,Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74. (Pubitemid 32878711)
13. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455:1069-75.
14. O'Shaughnessy JO, Osborne C, Pippen J, Yoffe M. Efficacy of BSI- 201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol 2009;27:Abstract 3.
15. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-11. (Pubitemid 39209661)
16. Sakaguchi T, Watanabe A, Sawada H, Yamada Y, Tatsumi M, Fujimoto H, et al. Characteristics and clinical outcome of proximal-third gastric cancer. J Am Coll Surg 1998;187:352-7. (Pubitemid 28467609)
17. Marrelli D, Roviello F, de Manzoni G, Morgagni P, Di Leo A, Saragoni L, et al. Different patterns of recurrence in gastric cancer depending on Lauren's histologic type: longitudinal study. World J Surg 2002;26: 1160-5. (Pubitemid 36920276)
18. Hofman M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, et al. Assessment of a Her2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797-805. (Pubitemid 351724903)
19. Shah MA, Yeung H, Coit D, Trocola R, Ilson D, Randazzo L, et al. A phase II study of preoperative chemotherapy with irinotecan(CPT) and cisplatin(CIS) for gastric cancer(NCI 5917): FDG-PET/CT predicts patient outcome. American Society of Clinical Oncology, Annual Proceedings, Orlando, FL; 2007:Abstract #4502.
20. Shah MA, Kelsen DP. Gastric cancer: A primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. J Natl Compr Canc Netw 2010;8:437-47.
21. D'Errico M, de Rinaldis E, Blasi MF, Viti V, Falchetti M, Calcagnile A, et al. Genome-wide expression profile of sporadic gastric cancers with microsatellite instability. Eur J Cancer 2009;45:461-9.
22. Ghosh D. Penalized discriminant methods for the classification of tumors from gene expression data. Biometrics 2003;59.
23. Hastie T, Tibshirani R, Buja A. Flexible discriminant analysis by optimal scoring. J Am Stat Assoc 1994;89:1255-70.
24. Efron B, Tibshirani R. On testing the significance of sets of genes. Ann Appl Stat 2007;1:107-29.
25. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57.
26. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 2010;28:1547-53.
27. Kang YK, Ohtsu A, Van Cutsem E, et al. AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). J Clin Oncol 2010;28:absLBA4007.
28. Study Group of Millennium Genome Project for Cancer, Sakamoto H, Yoshimura K, Saeki N, Katai H, Shimoda T, et al. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet 2008;40:730-40.
29. Saeki N, Gu J, Yoshida T, Wu X. Prostate stem cell antigen: a Jekyll and Hyde molecule? Clin Cancer Res 2010;16:3533-8.
30. Leung SY, Chen X, Chu KM, Yuen ST, Mathy J, Ji J, et al. Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastases. Proc Natl Acad Sci U S A 2002;99:16203-8. (Pubitemid 35462773)
31. Ganesan K, Ivanova T, Wu Y, Rajasegaran V, Wu J, Lee MH, et al. Inhibition of gastric cancer invasion and metastases by PLA2G2A, a novel beta-catenin/TCF target gene. Cancer Res 2008;68:4277-86.
32. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33.
33. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515-27. (Pubitemid 44854747)
34. Becker M, Sommer A, Kr€atzschmar JR, Seidel H, Pohlenz HD, Fichtner I, et al. Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM. Mol Cancer Ther 2005;4:151-68. (Pubitemid 40268073)
35. Ooi CH, Ivanova T, Wu J, Lee M, Tan IB, Tao J, et al. Oncogenic pathway combinations predict clinical prognosis in gastric cancer. PLos Genet 2009;5:e1000676.
36. Hiyama T, Haruma K, Kitadai Y, Masuda H, Miyamoto M, Tanaka S, et al. K-ras mutation in Helicobacter pylori-associated chronic gastritis in patietns with and without gastric cancer. Int J Cancer 2002;97:562-6. (Pubitemid 34087791)
37. Tay ST, Leong SH, Yu K, Aggarwal A, Tan SY, Lee CH, et al. A combined comparative genomic hybridization and expression microarray analysis of gastric cancer reveals novel molecular subtypes. Cancer Res 2003;63:3309-16. (Pubitemid 36735888)
38. Correa P, Shiao YH. Phenotypic and genotypic events in gastric carcinogenesis. Cancer Res 1994;54Suppl:1941s-43s.
39. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of Her2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010. [Epub ahead of print].
40. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34.
41. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-502. (Pubitemid 43854964)